Assembly Biosciences, Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Assembly Biosciences, Inc. (ASMB) is a biotechnology company developing therapeutics for serious viral diseases, including recurrent genital herpes, hepatitis B (HBV), hepatitis delta (HDV), and transplant-related herpesviruses. The Company operates as a single segment and is currently in the clinical development stage with no approved products.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $8.2 million | $9.4 million |
| Total Operating Expenses | $19.6 million | $19.4 million |
| Net Loss | $(9.1) million | $(8.8) million |
| Net Loss Per Share (Basic & Diluted) | $(0.54) | $(1.17) |
| Cash, Cash Equivalents & Marketable Securities | $226.6 million | $213.0 million (approx.) |
| Net Cash Used in Operating Activities | $(22.1) million | $(23.4) million |
| Deferred Revenue (Gilead Collaboration) | $29.1 million | $36.9 million |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by 13% ($1.2 million) compared to Q1 2025, attributed to the timing of activities and progress toward completion of services under the Gilead Collaboration Agreement.
- Expense Stability: Total operating expenses remained flat at approximately $19.6 million. Research and Development (R&D) expenses were $14.9 million, unchanged from the prior year, driven by increased employee-related costs offset by decreased external program expenses for candidates 5366, 6250, and 4334.
- Improved EPS: Net loss per share improved significantly from $(1.17) to $(0.54) due to a substantial increase in the weighted average shares outstanding (from 7.5 million to 16.9 million) following equity issuances in 2025.
- Interest Income Surge: Interest and other income increased 104% to $2.3 million, driven by a larger investment portfolio balance following financing proceeds and the $35.0 million payment received from Gilead in December 2025.
Guidance, Outlook, and Management Commentary
- Liquidity: As of March 31, 2026, the Company held $226.6 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations into 2028.
- Gilead Collaboration: In December 2025, Gilead exercised its option to exclusively license the Company's Helicase-Primase Inhibitor (HPI) program (candidates 5366 and 1179) for recurrent genital herpes. The Company received a net payment of $35.0 million. Gilead will control further development and commercialization.
- Pipeline Updates:
- 5366 & 1179: Phase 1a/b studies completed; transition to Gilead is ongoing. Gilead is expected to initiate Phase 2 studies in 2026.
- 6250 (HDV): Phase 1a completed; Phase 2 initiation expected in Q4 2026.
- 4334 (HBV): Gilead declined to exercise its option in March 2026. The Company retains full control and is actively seeking partners; it does not plan to advance 4334 without a partner.
- 7272 (NNPI): Undergoing regulatory filing-enabling studies.
- Risks: Key risks include the Company's lack of profitability, dependence on the Gilead collaboration for future funding and development of key assets, and the inherent uncertainties of clinical development and regulatory approval.
Investor Verification Checklist
- Verify the specific terms of the "Profit-Share" option regarding the HPI program (40% cost/profit share in the U.S.) and the timeline for the Company's decision (mid-2026).
- Confirm the status of the search for a partner for the 4334 (HBV) program following Gilead's option decline.
- Review the detailed breakdown of the $226.6 million cash position to understand the maturity profile of marketable securities.
- Monitor the timeline for the initiation of Phase 2 studies for the HPI program by Gilead and the HDV program (6250) by Assembly.
- Assess the impact of the significant share count increase (dilution) on future earnings per share calculations.